[Skip to Content]
[Skip to Content Landing]
December 12, 1977

Protective Efficacy of Pneumococcal Polysaccharide Vaccines

Author Affiliations

From the Gold Fields of South Africa (Drs Smit and Oberholzer) and the South African Institute for Medical Research (Mr Hayden-Smith and Dr Koornhof), Johannesburg, South Africa, and from the Division of Virus and Cell Biology Research, Merck Institute for Therapeutic Research, West Point, Pa (Dr Hilleman).

JAMA. 1977;238(24):2613-2616. doi:10.1001/jama.1977.03280250039019

Clinical studies of 6- and 12-valent pneumococcal capsular polysaccharide vaccines were carried out in controlled studies among novice gold miners in South Africa. In the studies 1,523 persons received pneumococcal vaccine, and 3,171 were included as controls. In the great majority of subjects given pneumococcal vaccine, antibodies developed against the capsular types included in the vaccine. The 6-valent vaccine afforded 76% reduction in cases of laboratory-verified pneumococcal pneumonia caused by the homologous types, and there was 92% reduction in the cases afforded by the 12-valent vaccine. The vaccines were well tolerated and offer great promise for effective control of illnesses caused by pneumococci.

(JAMA 238:2613-2616, 1977)